← ANALYST RATINGS · TIPRANKS
Crispr Therapeutics AG (CRSP): analyst forecast and price target
Analyst consensus
Moderate Buy8 Buy6 Hold0 Sell
Ratings of 14 analysts in the last 3 months12-month forecast
Based on 14 price targets given in the last 3 months, the average target is $71.85, the highest $110, the lowest $45.00. The average is +45.9% from the last price of $49.25.
Analyst ratings 22
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $51.00 → $50.00−2.0% | Hold | +1.5% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $51.00 → $50.00−2.0% | Hold | +1.5% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $51.00 → $50.00−2.0% | Hold | +1.5% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $49.00 → $48.00−2.0% | Hold | −2.5% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $52.00 → $51.00−1.9% | Hold | +3.6% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $51.00 → $50.00−2.0% | Hold | +1.5% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | $52.00 | Hold | +5.6% | Initiated | 14.10.26on TipRanks 19:50 | +2.3%next day −3.3% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $82.00 → $81.00−1.2% | Buy | +64.5% | Reiterated | 09.10.26on TipRanks 08:30 | +5.2%next day −3.4% · 5 days −5.8% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $80.00 | Buy | +62.4% | Reiterated | 09.10.26on TipRanks 06:25 | +5.2%next day −3.4% · 5 days −5.8% | ↗ |
| Gil Blum★★★★★★★★★★#949 · hits 43% · avg +12.5% | Needham | $82.00 | Buy | +66.5% | Reiterated | 05.10.26on TipRanks 06:45 | +2.8%next day −6.4% · 5 days −10.5% | ↗ |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $75.00 | Hold | +52.3% | Reiterated | 02.10.26on TipRanks Oct 5 08:13 | −0.8%next day +2.8% · 5 days −4.8% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $88.00 | Buy | +78.7% | Reiterated | 04.09.26on TipRanks Sep 7 10:16 | −0.9%next day −1.3% · 5 days −3.9% | ↗ |
| Jonathan Miller★★★★★★★★★★#10361 · hits 41% · avg −3.3% | Evercore ISI | $76.00 | Buy | +54.3% | Reiterated | 31.08.26on TipRanks 09:15 | −1.0%next day +0.4% · 5 days −3.7% | ↗ |
| Sami Corwin★★★★★★★★★★#511 · hits 55% · avg +18.5% | William Blair | — | Buy | — | Reiterated | 28.08.26on TipRanks 15:25 | −2.6%next day −1.0% · 5 days −3.5% | ↗ |
| Maxwell Skor★★★★★★★★★★#486 · hits 74% · avg +28.0% | Morgan Stanley | $60.00 | Hold | +21.8% | Reiterated | 28.08.26on TipRanks 12:26 | −2.6%next day −1.0% · 5 days −3.5% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $48.00 → $55.00+14.6% | Hold | +11.7% | Assigned | 10.08.26on TipRanks Aug 6 09:40 | −1.4%next day +3.0% · 5 days +3.3% | ↗ |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $110 | Buy | +123.4% | Reiterated | 04.08.26on TipRanks 07:45 | +5.3%next day −1.0% · 5 days +2.0% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $50.00 | Hold | +1.5% | Reiterated | 03.08.26on TipRanks Aug 5 21:45 | +1.9%next day +5.3% · 5 days +5.9% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | $45.00 | Hold | −8.6% | Reiterated | 03.08.26on TipRanks Aug 4 01:20 | +1.9%next day +5.3% · 5 days +5.9% | ↗ |
| Silvan Turkcan★★★★★★★★★★#10721 · hits 17% · avg −13.5% | Citizens JMP | $80.00 | Buy | +62.4% | Reiterated | 22.07.26on TipRanks Jul 29 02:30 | −1.8%next day +1.8% · 5 days +3.2% | ↗ |
| Unknown Analyst | Mizuho Securities | $85.00 | Buy | +72.6% | Reiterated | 10.06.26on TipRanks Jun 11 04:30 | −2.4%next day −0.1% · 5 days +5.2% | ↗ |
| William Pickering★★★★★★★★★★#5908 · hits 58% · avg +1.8% | Bernstein | $50.00 → $56.00+12.0% | Hold | +13.7% | Assigned | 13.05.26on TipRanks 06:35 | −0.7%next day −5.1% · 5 days −7.8% | ↗ |
| Geulah Livshits★★★★★★★★★★#2175 · hits 35% · avg +7.2% | Chardan Capital | $76.00 | Buy | +54.3% | Reiterated | 04.05.26on TipRanks 22:30 | −3.0%next day +3.8% · 5 days −1.1% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $69.00 → $67.00−2.9% | Buy | +36.0% | Reiterated | 13.02.26on TipRanks Feb 16 08:05 | +8.4%next day 0.0% · 5 days +1.6% | ↗ |
| Unknown Analyst | Oppenheimer | $95.00 | Buy | +92.9% | Reiterated | 11.11.25on TipRanks 08:45 | +0.9%next day −5.5% · 5 days +0.2% | ↗ |
| Jack Allen★★★★★★★★★★#12322 · hits 30% · avg −16.3% | Robert W. Baird | $52.00 → $44.00−15.4% | Hold | −10.7% | Reiterated | 11.11.25on TipRanks 07:35 | +0.9%next day −5.5% · 5 days +0.2% | ↗ |
| Gena Wang★★★★★★★★★★#4240 · hits 44% · avg +2.4% | Barclays | $56.00 | Hold | +13.7% | Reiterated | 11.11.25on TipRanks 04:00 | +0.9%next day −5.5% · 5 days +0.2% | ↗ |
| William Maughan★★★★★★★★★★#1398 · hits 46% · avg +16.2% | Clear Street | $52.00 → $50.00−3.8% | Hold | +1.5% | Reiterated | 11.11.25on TipRanks Nov 10 15:25 | −2.5%next day +0.9% · 5 days +3.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Crispr Therapeutics AG
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $73.58 at a price of $55.32 (+33.0%); now: $71.85 at $49.25 (+45.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 8 | 7 |
| Buy | 6 | 6 | 7 | 8 | 7 | 7 |
| Hold | 5 | 5 | 6 | 8 | 7 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.04 (from $-1.50 to $-0.46). Last quarter: $-0.94.
Sales
Next quarter’s sales estimate — $15M (from $0M to $77M). Last quarter: $10M.
Best top-analyst consensus in the sector · Healthcare
About Crispr Therapeutics AG
- CEO: Samarth Kulkarni
- Employees: 393
- Baarerstrasse 14, Zug, ZG, 6300, CH
- www.crisprtx.com
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
Data from the stock’s TipRanks forecast page, read 24 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗